Credits: Canva
An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.
One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.
Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.
The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.
The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.
Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”
The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.
Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.
The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.
Credit: iStock
Pennsylvania has reported the first two measles-related deaths of 2026 in the US, both involving unvaccinated individuals. One was reportedly an infant, while details about the second person have not been released.
While the cause of the infant’s death is disputed, Lancaster County Coroner confirmed that measles antibodies were found in postmortem testing, raising significant concerns
According to the Pennsylvania Department of Health (DOH), the deaths mark the first measles-related deaths in the state in 35 years.
Pennsylvania Reports 424 Measles Cases
Pennsylvania is among the hardest-hit states in the US outbreak, with 424 cases reported across 28 counties, including 94 in the past week. At least 73 people have been hospitalized with measles complications.
Lancaster County has reported 197 confirmed cases. The county also has a low MMR vaccination rate, with coverage falling from 95.5% in 2017 to 87.6% last year. Local physicians and health officials say the actual case count is likely higher.
Infants Face Higher Risk
The first MMR dose is recommended at 12 to 15 months, followed by a second dose at 4 to 6 years.
“The real vulnerability is in infants between 6 and 11 months of age, as maternal antibody is waning and they haven’t gotten their first dose of the MMR vaccine,” said Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Dallas.
In areas with high measles exposure, health authorities may recommend an early MMR dose from 6 months of age. This was done during last year’s Texas outbreak, when two unvaccinated girls died of measles.
Questions Over the Reported Deaths
Gov. Josh Shapiro and Health Secretary Debra Bogen announced the two deaths at a Tuesday press conference in Lancaster County and urged people to get vaccinated.
“We hope and we pray that those deaths will be the last,” Shapiro said. “This illness and death from measles is completely preventable.”
The state initially withheld details, citing privacy concerns. The lack of information prompted questions from local officials and lawmakers.
Republican Sen. Scott Martin said the announcement had not been independently verified. Republican Rep. Dave Zimmerman called for more information, while county commissioner Josh Parsons said the local coroner could not confirm any measles deaths.
Coroner Says Infant Did Not Die From Measles
The state confirmed information about the infant’s death on Wednesday after Lancaster County Coroner Stephen Diamantoni said his office was investigating a newborn who tested positive for measles and died from a ruptured spleen.
Diamantoni said the newborn died shortly after birth from a laceration of the spleen, not measles, although measles antibodies were found in postmortem testing.
“The newborn had measles” but did not “die of measles,” Parsons said, citing the coroner.
No details have been released about the second person whose death was announced by the state.
Shapiro, Kennedy Clash Over Vaccination Rates
Shapiro blamed Health Secretary Robert F. Kennedy Jr.’s policies and rhetoric for contributing to outbreaks.
Kennedy rejected the claim, saying Pennsylvania’s vaccination decline began before his tenure and arguing that distrust created during the Covid-19 pandemic had weakened confidence in vaccines.
US Reports 2,777 Measles Cases
The US has confirmed 2,777 measles cases this year, the highest number in 35 years.
Measles has been considered eliminated in the US since 2000 because it has not continuously spread for a year. The Pan American Health Organization is expected to decide in November whether the US has lost its elimination status.

Credit: X
For elite athletes, stepping away from competition can look like giving up. For American tennis star Amanda Anisimova, it turned out to be an important part of finding her way back.
Anisimova stepped away from professional tennis in 2023, citing burnout and struggles with her mental health. Three years later, she says the experience has changed how she recognises stress and protects her wellbeing.
Her story depicts what burnout can do to athletes and why taking a break can sometimes be part of recovery rather than a setback.
In May 2023, Anisimova announced an indefinite break from tennis, saying she had been struggling with mental health and burnout since the previous summer.
At the time, she was just 21 and already an established professional. She later described the decision as one of the hardest she had made because she feared losing the ranking she had worked so hard to build.
In a recent interview with The Guardian, Anisimova said she now recognises warning signs much earlier. She said there are days when feeling tired or unmotivated is normal, but it becomes concerning when those feelings keep happening and begin affecting how a person functions.
Also read: Student Mental Health Needs More Than A Counsellor
Athlete burnout is not simply being exhausted after a demanding tournament. It can involve emotional and physical exhaustion, reduced motivation, irritability, loss of enjoyment and a sense of detachment from the sport.
Constant training, competition, travel, injuries, pressure to perform and the expectation to remain competitive can contribute to burnout.
For professional athletes, the distinction between work and personal life can also become blurred. Tennis players in particular spend much of the year travelling from tournament to tournament. They get little opportunity to establish a normal routine.
Anisimova said that spending time at home, nurturing social connections and doing things that are not related to her sport have become important parts of maintaining that balance.
She said, "That’s something that I used to not prioritise so much: how to recharge myself and take time for myself, prioritise my wellbeing off the court. In the past, it was really just a lot of tennis and I didn’t really know how to incorporate those small breaks for myself. I think that’s a big reason why I reached such a breaking point and needed to take that time away from the sport.”
During her time away, Anisimova returned to some ordinary activities that had little to do with tennis. She painted, spent time with friends and family, studied and took a step back from the tournament calendar.
She later described the experience as “very refreshing”, saying she regained energy and happiness after getting away from professional tennis.
The important point is that recovery does not mean not pursuing your passion indefinitely. A break can help identify what is causing exhaustion and rebuild routines that support physical and mental recovery.
Also read: Long Working Hours Alter Our Brain Structure
Anisimova's experience also highlights why recognising early warning signs of burnout is important. Persistent exhaustion, losing interest in something once enjoyed, constantly feeling overwhelmed, irritability, sleep problems and declining performance can all signal that an athlete needs to reassess their workload and seek support.
In her recent interview, Anisimova said she now tries to “catch the signs a lot earlier” and give herself time to reset before reaching the point she did in 2023.
She has also said that prioritising her mental health made her a stronger athlete. “I don't think I would be where I'm at in my career if it wasn't for my break,” she said in a recent interview.
Anisimova returned to competition in 2024 and subsequently produced the strongest stretch of her career, including reaching the Wimbledon and US Open finals in 2025 and climbing as high as world No. 3 in 2026.
Credit: X
Doctors in London have performed the world’s first brain tumour surgery assisted by artificial intelligence. AI analysed the operation live, helping surgeons assess critical structures and protect the patient’s vision.
The procedure was carried out in May at the National Hospital for Neurology and Neurosurgery, part of University College London Hospitals (UCLH). The first patient, 48-year-old Rhys Hibbert, had an 11-mm tumour on his pituitary gland that had begun affecting his vision.
Hibbert’s vision had deteriorated to the point that he was using walking sticks. After surgery, he said he could see clearly when he woke up and was walking independently without glasses or sticks within a week.
To answer the biggest question, the AI did not perform the surgery. The neurosurgeon was in complete control the whole time. The technology, instead, analysed live video from the surgical camera in real time. It identified and highlighted important structures in the brain, including blood vessels and nerves related to vision.
The pituitary gland is roughly the size of a marble, but it is located in a crowded and packed region at the base of the brain. It is surrounded by the optic nerves and major blood vessels. A tumour in this area can therefore cause vision problems by pressing against the nerves.
It's extremely delicate work as the pituitary gland, optic nerves and blood vessels are packed into an extremely small area. According to UCLH, being just a millimetre off target can potentially result in blindness, stroke or death.
Also read: Daraxonrasib: US FDA Approves Once-Daily Pill for Metastatic Pancreatic Cancer
In Hibbert's case, the tumour had been discovered after he collapsed and suffered a seizure in December 2024. His symptoms later progressed to hormone imbalance and worsening vision.
Consultant neurosurgeon Professor Hani Marcus, who performed the operation alongside surgical resident Danyal Khan, said, “Huge thanks to the trial participants and to the team committed to improving patient outcomes by taking this important first step globally.”
The AI therefore acted more like an additional set of highly trained eyes, helping surgeons steer clear of the areas that needed to be avoided while removing as much of the tumour as safely possible.
The system was developed by researchers at the UCL Hawkes Institute and trained AI with hundreds of videos from previous endoscopic pituitary surgeries.
Dr Sophia Bano, Associate Professor in Robotics and Artificial Intelligence at UCL and technical lead for the system, said the AI had been exposed to a breadth of surgical examples that would take a human surgeon many years to learn.
She said, “It is designed to help recognise critical anatomy, surgical instruments and tissue interactions in real time, supporting the surgeon during highly delicate procedures.”
The technology can also potentially track surgical instruments and how they interact with tissue, allowing the possibility of giving surgeons additional feedback during complex procedures.
The significance of the procedure lies in real-time assistance. The surgeon interprets what is happening, makes decisions and controls the instruments, while the AI provides valuable additional information about the anatomy.
Health Innovation Minister James Frith described the procedure as an example of AI's potential in healthcare, while stressing that safeguards remain essential. He said, “AI needs proper safeguards and we will always ensure that safety is taken seriously.”
© 2024 Bennett, Coleman & Company Limited